# Sources — Ida B. Wells

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 5, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. National Park Service. “Ida B. Wells.” Supports her birth into slavery in Holly Springs, Mississippi, on July 16, 1862; the loss of both parents and one of her siblings to yellow fever when she was 16; her marriage to Ferdinand Barnett in 1895, with four children, keeping her own name; that she is considered a founder of the NAACP and later cut ties with it; and her death of kidney disease on March 25, 1931, in Chicago. https://www.nps.gov/people/idabwells.htm
2. National Women’s History Museum. “Ida B. Wells-Barnett.” Supports her birth into slavery in 1862, her parents’ deaths in the 1878 yellow fever epidemic when she was 16 and her care of her siblings, her journalism and *A Red Record* (1895), her exclusion from the NAACP’s “Founding Forty,” and her unsuccessful run for the Illinois State Senate in 1930. It gives her death, from kidney disease, as March 15, 1931 (see Conflicts). https://www.womenshistory.org/education-resources/biographies/ida-b-wells-barnett
3. *Women in World History: A Biographical Encyclopedia*, “Wells-Barnett, Ida (1862–1931),” via Encyclopedia.com (Gale). Supports the deaths of her parents and an infant brother in the yellow fever epidemic of September 1878, when she was 16; her four children, the youngest Alfreda M. Duster; and her death of uremia (“uremic poisoning”) in Chicago on March 25, 1931. https://encyclopedia.com/women/encyclopedias-almanacs-transcripts-and-maps/wells-barnett-ida-1862-1931
4. DeCosta-Willis M. “Wells-Barnett, Ida B.,” *Tennessee Encyclopedia* (Tennessee Historical Society). Supports her birth into slavery in Holly Springs on July 16, 1862; being orphaned by the 1878 epidemic; her marriage to Ferdinand L. Barnett on June 27, 1895; her signing of the call for the conference that led to the NAACP; and that “after a brief illness” she died on March 25, 1931 (at “sixty-nine,” see Conflicts). https://tennesseeencyclopedia.net/entries/ida-b-wells-barnett/
5. University of Chicago Library, Hanna Holborn Gray Special Collections Research Center. Guide to the Ida B. Wells Papers 1884–1976, biographical note. Supports her teaching at 16 after both parents died of yellow fever in 1878; the role of her Negro Fellowship League in the founding of the NAACP; her unsuccessful run for state senator in 1930; and the autobiography she began in 1927, edited by Alfreda M. Duster and published as *Crusade for Justice*. It gives her death as March 21, 1931 (see Conflicts). https://www.lib.uchicago.edu/e/scrc/findingaids/view.php?eadid=ICU.SPCL.IBWELLS
6. HISTMED Master Roster v3. Internal project source; not treated as independent corroboration.

## Clinical guidance

1. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (PMID 38490803): race-free eGFR with cystatin C when decisions depend on accuracy, staging on the G and A heat map, the kidney failure risk equation, evaluation of cause, an ARB at the highest tolerated dose for albuminuria, an SGLT2 inhibitor at eGFR 20 or above with albuminuria of 200 mg/g or more, statins for adults 50 or older with eGFR below 60, avoiding nephrotoxins, genetic testing and counseling, and planning for kidney replacement. https://pubmed.ncbi.nlm.nih.gov/38490803/
2. Delgado C, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. *J Am Soc Nephrol* 2021 (PMID 34556489; also *Am J Kidney Dis* 2022, PMID 34563581): adopt the race-free CKD-EPI 2021 creatinine equation and use cystatin C more widely, ending a race coefficient that raised eGFR for Black patients and delayed diagnosis, referral and transplant listing. https://pubmed.ncbi.nlm.nih.gov/34556489/
3. Inker LA, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. *N Engl J Med* 2021 (PMID 34554658). https://pubmed.ncbi.nlm.nih.gov/34554658/
4. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (PMID 33637192): standardized office measurement and a systolic target below 120 mmHg when tolerated. https://pubmed.ncbi.nlm.nih.gov/33637192/
5. Executive summary of the 2017 KDIGO CKD-MBD Guideline Update (PMID 28646995): calcium, phosphate, PTH and 25-hydroxyvitamin D from G3a, and correction of vitamin D deficiency. https://pubmed.ncbi.nlm.nih.gov/28646995/
6. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (PMID 40815242): home confirmation and a goal below 130/80. https://pubmed.ncbi.nlm.nih.gov/40815242/
7. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), chronic kidney disease, hypertension, anemia and depression monographs: potassium and creatinine two to four weeks after starting or increasing an ARB or SGLT2 inhibitor, eGFR and UACR by risk tier, calcium, phosphate and PTH at G3, hemoglobin yearly at G3, a lipid panel once at diagnosis, the kidney failure risk equation, nephrology at a 5-year risk of 3 to 5% or more, medication review and vaccination review. https://patrickrutledge.github.io/topthirty/
8. Centers for Disease Control and Prevention. Adult Immunization Schedule by Age. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html
9. Centers for Medicare & Medicaid Services. Medicare Wellness Visits. https://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/preventive-services/medicare-wellness-visits.html
10. U.S. Preventive Services Task Force: depression (2023), breast cancer (2024), colorectal cancer (2021), osteoporosis (2025), and falls prevention (2024). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
11. Medicare Preventive Services reference (Aether Forge, 2026). https://patrickrutledge.github.io/preventative_services/

## Editorial resolutions

- **Recent-death rule.** She died in 1931, so the rule does not apply. The record still uses only what the cited sources say about her health, which is very little: the brief final illness and its cause, kidney disease or uremia (CLM-0008).
- **What is documented and what is interpretation.** Her death after a brief illness from kidney disease (uremia) is **D**. Whether she had chronic kidney disease before that illness, and its cause, is not recorded; CLM-0009 states this as **R** with certainty “possible” and names the possibilities without choosing one. The modern episode is linked to these claims as a teaching anchor, not as a diagnosis of her real kidneys. No other illness, symptom or treatment from her life was found in the fetched sources, and none is added.
- **What could not be verified and was left out.** The Chicago Defender’s report of her death, Paula Giddings’s biography *Ida: A Sword Among Lions* and *Crusade for Justice* itself could not be read directly, so nothing is taken from them beyond what the fetched sources report (the title and editor of the autobiography). The Library of Congress pages could not be fetched (blocked). No fetched source names the day the final illness began, its symptoms or its course, so none is given. The age, name and cause of death of the infant brother beyond what Women in World History says are not used; a sister’s disability mentioned in one source is not used, because it is not needed and would add a health fact about another real person.
- **Conflicts.** Death date: March 25, 1931 (National Park Service, Tennessee Encyclopedia, Women in World History) is preferred; March 15 (National Women’s History Museum) and March 21 (University of Chicago Library) are recorded as conflicting alternatives. Age at death: 68 by her birth date; the Tennessee Encyclopedia says sixty-nine. The year she began the autobiography is given as 1927 by the University of Chicago Library and is used only in the timeline. The NAACP claim keeps both the founder status and her exclusion from the founding list.
- **Display name and alias.** The display name is “Ida B. Wells.” She used “Ida B. Wells-Barnett” after her marriage; it appears in no other record and is the only alias. No other figure who has a record is named.
- **Index age and dates.** The index visit on January 5, 2026 maps to January 5, 1931, when she was 68, about ten weeks before her death. The synthetic date of birth is July 16, 1957 (shift 95 years). The chronic-care visits on January 20, February 3 and March 3, 2026 and the annual wellness visit on February 17, 2026 map to the same days of 1931, all before the earliest reported death date (March 15) and before any reported final illness. The short window is the reason for the compressed schedule: two weeks to the consultation, two weeks after losartan, and four weeks after dapagliflozin, which are the CMID intervals for these checks. Checks planned after the last visit (potassium and creatinine after the losartan increase, urine albumin, hemoglobin, PTH and vitamin D at three months, and the nephrology review) are recorded as ordered or due; no result is invented for them. There is no past medical history before the index date, because none is documented.
- **No sick visit.** An acute illness weeks before her documented brief final illness would read as a hypothesis about that illness, so no sick visit is added. Sick-day rules for losartan and dapagliflozin are taught at every visit instead.
- **Synthetic clinical picture.** Every finding is synthetic. Following the presenting-problem pattern, intake records tiredness and ankle swelling with abnormal kidney tests (R94.4) and an elevated blood pressure reading (R03.0), both resolved at two weeks when the repeat urine test, the outside result, the ultrasound and home readings established hypertensive chronic kidney disease G3b A2 (I12.9, N18.32), anemia of chronic kidney disease (D63.1) and vitamin D deficiency (E55.9), all recorded then. Intake text shows only what was known at intake. Laboratory values are chosen so that the race-free CKD-EPI 2021 equations give eGFR 40 (creatinine) and 38 (creatinine with cystatin C); the script also computes the older race-based value (44) and the outside result two years earlier (64 race-based, 59 race-free) for the equity teaching point. The kidney failure risk (6.6% at 5 years, 2.2% at 2 years) is computed with the four-variable equation. Qualitative results (urinalysis, protein electrophoresis and free light chains, hepatitis and HIV serology, ultrasound, ECG, fundi) appear only in note text. Height (157 cm) and weights are synthetic.
- **Equity in diagnosis.** The teaching point is that a race coefficient once raised eGFR for Black patients, so her outside result two years earlier was reported as normal; the race-free equation shows the disease then. The record presents this as a feature of the equation and the system, citing the NKF-ASN Task Force, and does not attribute it to any person. The consultant also names APOL1-associated disease as possible without making ancestry a diagnosis.
- **APOL1 testing.** Offered with counseling at the consultation; she chose to defer it (GOAL-004, INT-008). No genetic result exists in the record, so no genetic claim is made about a real person.
- **Real people.** Her husband appears in the marriage claim and as part of her household only; her daughter appears only as the editor of the autobiography; her parents and infant brother appear only in the family history. No modern decision, statement or health fact is attributed to any real person.
- **Medicines.** Naproxen (over the counter) is stopped at intake and named only in text. Losartan 50 mg, then 100 mg; dapagliflozin 10 mg, started two weeks after losartan so that each eGFR change can be read; atorvastatin 20 mg without a routine repeat lipid panel, as KDIGO and the CMID advise (the ACC/AHA approach of repeat testing differs); vitamin D3; acetaminophen. Finerenone is discussed and not used, because she does not have diabetes.
- **Annual wellness visit.** A subsequent annual wellness visit at 68 (HCPCS G0439 and CPT 99497 in plain text) with the Mini-Cog, PHQ-2, AUDIT-C and Timed Up and Go; mammogram, bone density scan and a stool immunochemical test ordered; hepatitis B dose 2, RSV and recombinant zoster dose 1 given; and advance care planning that records her own synthetic wishes about kidney replacement options (transplant assessment, home dialysis preferred to center dialysis, conservative care explained) with an unnamed agent.
- **Focused visits.** The three chronic-care follow-ups (two weeks with the consultation, two weeks after losartan, and four weeks after dapagliflozin) are documented as focused visits on the CMID chronic kidney disease, hypertension and anemia monographs, KDIGO 2024, the KDIGO 2021 blood pressure guideline, the KDIGO 2017 CKD-MBD update and the 2025 AHA/ACC guideline. No protocol deviation occurred within the episode: each potassium and creatinine check fell within the two-to-four-week window; items due after the last visit are recorded as due or ordered.
- **Consultation.** The referral and the consultation by Emeka Lindqvist-Moore, MD (a fictional nephrologist), on the day of the two-week visit, are **S**. The consultant answers the six referral questions in line with what the record shows afterwards: hypertensive kidney disease most likely, APOL1-associated disease possible, no biopsy now; race-free staging confirmed, with cystatin C for decisions that depend on accuracy; APOL1 testing offered and deferred by her; losartan, then dapagliflozin, then losartan 100 mg (all done, with potassium at most 4.9 mmol/L and an eGFR dip of about 10%); vitamin D replacement with PTH rechecked at three months (due); and nephrology review at three months, with transplant evaluation when eGFR approaches 20.
